GE vs LLY: Which Is the Better Buy?
Side-by-side comparison of GE Aerospace and Eli Lilly and Company — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
GE Aerospace · Industrials
$312.90
+3.4% upside to fair value
Med Conviction
Grade C
High Quality
VS
Eli Lilly and Company · Healthcare
$1,183.72
+2.1% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
GE has more upside to fair value
(+3.4%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
GE |
LLY |
| Current Price |
$312.90 |
$1,183.72 |
| Fair Value Estimate |
$323.41 |
$1,208.00 |
| Upside to Fair Value |
+3.4%
|
+2.1%
|
| Market Cap |
$324.6B |
$1,114.8B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
27.4x
|
26.8x
|
| Price / Sales |
6.4x
|
14.0x
|
| Price / FCF |
38.7x
|
52.7x
|
| Revenue Growth YoY |
+21.1%
|
+47.7%
|
| Gross Margin |
35.4%
|
83.4%
|
| Operating Margin |
20.8%
|
49.7%
|
| Return on Equity |
49.0%
|
92.6%
|
| Dividend Yield |
0.53% |
0.57% |
| FCF Yield |
2.58%
|
1.9%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
GE Aerospace is a high-quality commercial and military propulsion company whose approximately 50,000 commercial-engine and 30,000 military-engine installed base, long-term service agreements, proprietary repair capabilities and certification barriers support recurring aftermarket economics. The business is executing strongly: revenue grew 21.1% year over year in the most recent quarter, while Q2 …
Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care. The business quality is high: TTM gross margin is 83.4%, TTM operating margin is 49.7%, TTM net margin is 33.5%, and ROE is 92.6%, while revenue grew 47.7% and earnings grew 25.3% in the most recent quarter on a year-over-year bas…
Accumulation Zones
| Metric |
GE |
LLY |
| Zone Low |
$242.56 |
$906.00 |
| Zone High |
$274.90 |
$1,026.80 |
| In Buy Zone? |
No
|
No
|